Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Equity (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Return on Equity for 6 consecutive years, with 0.52% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 4701.0% to 0.52% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.52% through Dec 2025, down 4701.0% year-over-year, with the annual reading at 0.48% for FY2025, 1538.0% up from the prior year.
  • Return on Equity hit 0.52% in Q4 2025 for Insight Molecular Diagnostics, down from 15.14% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 56.98% in Q1 2025 to a low of 11.27% in Q2 2025.
  • Historically, Return on Equity has averaged 4.85% across 5 years, with a median of 0.74% in 2021.
  • Biggest YoY gain for Return on Equity was 5755bps in 2025; the steepest drop was -4701bps in 2025.
  • Year by year, Return on Equity stood at 0.78% in 2021, then dropped by -26bps to 0.98% in 2022, then surged by 89bps to 0.1% in 2023, then skyrocketed by 46074bps to 47.52% in 2024, then tumbled by -99bps to 0.52% in 2025.
  • Business Quant data shows Return on Equity for IMDX at 0.52% in Q4 2025, 15.14% in Q3 2025, and 11.27% in Q2 2025.